Correspondingly, the TGF-β pathway could be a point of focus for an anticancer pharmacological approach, specifically regarding the main mediator of TGF-β activities facilitating immunosuppression and stimulating angiogenesis, as well as EMT in cancer cells [4]. This evidence concerns the gene TGFB1 and cancer.